enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
enGene Holdings (Nasdaq: ENGN) announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. CEO Ron Cooper and CMO Dr. Raj Pruthi will engage in a fireside chat on November 12, 2024, at 10:30 a.m. ET. The company's lead investigational product, detalimogene voraplasmid, is currently in a pivotal study targeting high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. The event will be webcast live on enGene's website and remain accessible for 90 days.
enGene Holdings (Nasdaq: ENGN) ha annunciato la sua partecipazione alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim. Il CEO Ron Cooper e il CMO Dr. Raj Pruthi parteciperanno a una conversazione informale il 12 novembre 2024, alle 10:30 ET. Il principale prodotto investigativo dell'azienda, detalimogene voraplasmid, è attualmente in uno studio pivotale che mira al cancro della vescica non muscolo-invasivo (NMIBC) ad alto rischio e non responsivo al BCG con carcinoma in situ. L'evento sarà trasmesso in diretta sul sito web di enGene e rimarrà accessibile per 90 giorni.
enGene Holdings (Nasdaq: ENGN) anunció su participación en la Conferencia Inaugural de Innovación en Salud de Guggenheim. El CEO Ron Cooper y el CMO Dr. Raj Pruthi participarán en una charla informal el 12 de noviembre de 2024, a las 10:30 a.m. ET. El principal producto en investigación de la compañía, detalimogene voraplasmid, se encuentra actualmente en un estudio pivotal dirigido a cáncer de vejiga no muscular invasivo (NMIBC) de alto riesgo que no responde al BCG con carcinoma in situ. El evento se transmitirá en vivo en el sitio web de enGene y estará accesible durante 90 días.
enGene Holdings (Nasdaq: ENGN)는 구겐하임의 첫 번째 의료 혁신 컨퍼런스에 참여한다고 발표했습니다. CEO 론 쿠퍼와 CMO 라지 프루티 박사는 2024년 11월 12일 오전 10시 30분 ET에 대담을 진행할 예정입니다. 회사의 주요 연구 제품인 데탈리모젠 바라플라스미드는 고위험 BCG 반응 없는 비근육 침습성 방광암(NMIBC)에서 제자리 암을 목표로 하는 중요한 연구에 있습니다. 이 행사는 enGene의 웹사이트에서 실시간으로 방송되며, 90일 동안 접근할 수 있습니다.
enGene Holdings (Nasdaq: ENGN) a annoncé sa participation à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim. Le PDG Ron Cooper et le CMO Dr. Raj Pruthi participeront à une discussion informelle le 12 novembre 2024 à 10h30 ET. Le principal produit d'investigation de l'entreprise, detalimogene voraplasmid, est actuellement dans une étude pivot ciblant le cancer de la vessie non musculaire invasif (NMIBC) à haut risque, non réactif au BCG, avec carcinome in situ. L'événement sera diffusé en direct sur le site web d'enGene et restera accessible pendant 90 jours.
enGene Holdings (Nasdaq: ENGN) gab seine Teilnahme an der Erstveranstaltung zur Gesundheitsinnovation von Guggenheim bekannt. CEO Ron Cooper und CMO Dr. Raj Pruthi werden am 12. November 2024 um 10:30 Uhr ET an einem informellen Gespräch teilnehmen. Das Hauptuntersuchungsprodukt des Unternehmens, detalimogene voraplasmid, befindet sich derzeit in einer entscheidenden Studie, die auf Hochrisiko-BCG-resistentes, nicht-muskelinvasives Blasenkarzinom (NMIBC) mit Carcinoma in situ abzielt. Die Veranstaltung wird live auf der Website von enGene übertragen und bleibt 90 Tage lang zugänglich.
- None.
- None.
A live webcast of the fireside chat can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid, (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) – a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105407693/en/
For media contact: media@engene.com
For investor contact: investors@engene.com
Source: enGene Holdings Inc.
FAQ
When is enGene (ENGN) presenting at Guggenheim's Healthcare Innovation Conference?
What is detalimogene voraplasmid being developed for by enGene (ENGN)?
How long will enGene's (ENGN) Guggenheim conference webcast be available?
Who will represent enGene (ENGN) at the Guggenheim Healthcare Conference?
